- Sobi’s EBITA for Q3 is reported at SEK 2.92 billion, surpassing the expected SEK 2.11 billion.
- The company achieved an EBITA margin of 42%, beating the forecasted 34.8%.
- Total revenue reached SEK 6.89 billion, exceeding the estimated SEK 6.05 billion.
- Elocta generated revenue of SEK 1.12 billion, slightly below the expected SEK 1.26 billion.
- Alprolix’s revenue was SEK 575 million, higher than the anticipated SEK 557.4 million.
- Kineret brought in SEK 699 million, above the estimate of SEK 641.1 million.
- Orfadin earned SEK 128 million, outperforming the expected SEK 108.8 million.
- Gamifant’s revenue was SEK 405 million, which fell short of the estimated SEK 487.7 million.
- EBIT was SEK 2.04 billion, significantly above the forecast of SEK 1.22 billion.
- Analysts’ ratings include 8 buys, 6 holds, and 1 sell for Sobi.
A look at Swedish Orphan Biovitrum AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Swedish Orphan Biovitrum AB (SOBI) has a promising long-term outlook, with strong scores across various factors according to Smartkarma Smart Scores. The company scores well in momentum, showing positive market trends and investor sentiment. This indicates that SOBI is currently performing well and is likely to continue on a positive trajectory.
Moreover, SOBI also demonstrates solid value, growth, and resilience scores, highlighting its potential for sustained growth and stability. Although the dividend score is lower, the overall outlook remains positive based on the other strong indicators. As a bio-pharmaceutical and bio-technology company focusing on therapies for various diseases, including haemophilia and inflammation, SOBI’s global reach positions it well for future success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
